-
Received a promising program aimed at preventing transmission of sexually transmitted diseases (STDs)? Circle Oct. 14 as the deadline for abstract submission for the 2012 National STD Prevention Conference March 12-15 in Minneapolis.
-
Field test results of a integrated microfluidic-based diagnostic device indicate that the potential "lab-on-a-chip" might be able to perform complex laboratory assays in a simple, convenient manner.
-
The Food and Drug Administration (FDA) added a "black box" warning in 2004 to the contraceptive injection depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City; Medroxyprogesterone Acetate Injectable Suspension USP, Teva Pharmaceuticals USA, North Wales, PA) advising that prolonged use might result in bone mineral density loss.
-
Alert your patients of a counterfeit form of emergency contraception (EC), labeled as Evital. The Food and Drug Administration (FDA) has issued a warning on the drug.
-
How many times have you prescribed oral contraceptives (OCs) for a woman at one visit, only to find that she has discontinued the method by the next exam due to financial inability to cover her insurance copay on the pill pack?
-
The American College of Obstetricians and Gynecologists (ACOG) has issued new breast cancer screening guidelines that recommend mammography screening be offered annually to women beginning at age 40.
-
Results of three large studies, presented at the recent International AIDS Society (IAS) Conference on HIV Pathogenesis, indicate that pre-exposure prophylaxis of antiretrovirals can prevent HIV when used by heterosexual men and women.
-
There are at least six different commonly used chemotherapeutic regimens in practice to treat patients with low-risk gestational trophoblastic neoplasia (GTN) with no consensus or previous formal evaluation as to which may be best.
-
The concept that "term" pregnancy applies to any pregnancy extending past 36 completed weeks has been recently strongly challenged.
-
Two independent case-control studies investigating the risk of venous thromboembolism (VTE) in users of oral contraceptives (OC) containing 30 mcg of ethinyl estradiol and a progestin component of either drospirenone or levonorgestrel found that VTE risk was two to three times higher in those using a drospirenone pill.